Business Context and Reporting Period
Company: Metavia Inc. (MTVA)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Metavia is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. Its primary programs are vanoglipel (for MASH and Type 2 Diabetes) and DA-1726 (for obesity). The company has no product revenue and relies on capital raising to fund operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3.82) million | $(3.67) million |
| Loss Per Share (Basic & Diluted) | $(0.79) | $(3.93) |
| Operating Expenses | $4.03 million | $3.89 million |
| Cash and Cash Equivalents (End of Period) | $13.73 million | $11.19 million |
| Net Cash Used in Operating Activities | $(4.26) million | $(4.82) million |
| Net Cash Provided by Financing Activities | $7.71 million | $(0.01) million |
| Total Assets | $14.39 million | $11.12 million (Dec 31, 2025) |
| Accumulated Deficit | $(152.65) million | $(139.53) million (Mar 31, 2025) |
Material Changes vs. Prior Period
- Capital Raise: In January 2026, the company closed an underwritten public offering, receiving net proceeds of $7.1 million. Additionally, $0.3 million was raised via an At-The-Market (ATM) offering in March 2026. This significantly improved liquidity compared to the prior year.
- Share Count: Weighted average shares outstanding increased from 933,109 in Q1 2025 to 4,859,567 in Q1 2026 due to the public offering and warrant exercises, diluting the loss per share impact.
- Operating Expenses: Total operating expenses increased slightly by 3.6% ($0.14 million).
- Research & Development (R&D): Decreased by 9.7% ($0.23 million) primarily due to reduced direct costs for the vanoglipel Phase 2a trial.
- General & Administrative (G&A): Increased by 23.4% ($0.37 million) driven by higher legal, professional, and consulting fees.
- Other Income: Total other income remained relatively flat at $0.20 million, consisting of interest income and gains from changes in the fair value of warrant liabilities.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. The company has an accumulated deficit of $152.7 million and expects to continue incurring losses. Continued operations depend on securing additional financing through equity offerings, debt, or collaborations.
- Clinical Pipeline Updates:
- DA-1726: Positive statistically significant results were announced in January 2026 for the Phase 1 trial. Phase 1, Part 3 (titration studies) began in April 2026, with data readouts expected in Q4 2026.
- Vanoglipel: The company expects to finalize the Clinical Study Report for the Phase 2a trial in the first half of 2026 and is working toward an end-of-Phase 2a meeting with the FDA.
- Related Party Transactions: The company has a significant payable of $3.0 million to Dong-A ST Co., Ltd. (related party) for shared services and manufacturing. Approximately $0.7 million of this was paid in April 2026, with the remainder due in June and September 2026.
- Warrant Liabilities: The company recorded a gain of $0.12 million from the change in fair value of warrant liabilities. Outstanding warrants include Series C and D warrants from the January 2026 offering, some of which are callable upon positive data readouts.
Investor Verification Checklist
- Cash Runway: Verify if the $13.7 million cash balance is sufficient to fund operations through the planned Q4 2026 data readouts given the $4.3 million quarterly burn rate.
- Related Party Payables: Confirm the payment schedule and terms for the $3.0 million owed to Dong-A ST to ensure no default risk.
- Dilution Risk: Assess the impact of outstanding warrants (over 10 million shares issuable) and the remaining $0.8 million ATM capacity on future share count.
- Clinical Milestones: Monitor the timeline for the vanoglipel Phase 2a Clinical Study Report and the DA-1726 Phase 1 Part 3 data readout, as these are critical for future financing.
- Going Concern Status: Review subsequent filings for any new financing announcements or restructuring of operations to mitigate the going concern warning.